Treatment of Active CLL with TP53 Mutation or del(17p)
Clinical Scenario
This protocol addresses patients with active chronic lymphocytic leukemia (CLL) whose tumour carries a TP53 gene mutation or deletion of the 17p locus (del(17p)) — the chromosomal region encoding the tumour protein p53. This molecular profile identifies a distinct, high-risk subpopulation requiring a dedicated treatment strategy.
Key Molecular Finding: TP53 Mutation / del(17p)
TP53 mutation or del(17p) is a critical determinant of therapy selection in active CLL. Conventional chemoimmunotherapy (CIT) is not an appropriate option for this subgroup, regardless of IGHV mutational status, due to poor prognosis with that approach.
Treatment Approach (partial overview)
Front-line therapy for this subgroup is centred on BTK inhibitor-based targeted treatment. The full protocol specifies multiple evidence-based options — including both single-agent and combination strategies, as well as guidance on additional interventions in eligible patients.
Complete regimen selection, sequencing, and clinical considerations are available in the full structured protocol below.
References
- TP53 mutation or del(17p): ibrutinib or acalabrutinib or venetoclax plus obinutuzumab or venetoclax alone or idelalisib plus rituximab [III, A].
- Patients with TP53 mutation or del(17p) should receive front-line therapy with BTKis [III, A]; CIT is not an option due to the poor prognosis with this therapy independent from IGHV status.
- Ibrutinib or acalabrutinib [I, A]
- Venetoclax+rituximab [I, A]
- Venetoclax alone [III, B]
- Idelalisib+rituximab [II, B]
- Consider alloSCT in fit patients
View source ↗